Sartorius Aktiengesellschaft (SRT3)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 273.50 |
|---|---|
| 52-week range | 198.50 – 282.20 |
| Return, 1 month / 3 months | +8.1% / +23.6% |
| Return, 1 year / 3 years | +14.5% / +15.0% |
| Trend | Uptrend |
| RSI (14) | 65 |
| Volatility (1 year) | 39.3% |
| Worst drawdown (1 year) | -22.5% |
| Average daily value traded | 23.48M EUR |
| Dividend yield | 0.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sartorius Aktiengesellschaft is a German supplier of laboratory and bioprocess equipment based in Göttingen. The company provides instruments and consumables such as balances, pipettes, filters and fermentation systems, along with services for laboratory work and pharmaceutical production. Its customers include research laboratories, universities and biopharmaceutical manufacturers that use its products in drug development and manufacturing processes. Sartorius operates through divisions focused on laboratory products and on bioprocess solutions for the life science industry.
Sartorius Aktiengesellschaft trades under the code SRT3 on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sartorius Aktiengesellschaft (SRT3) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 273.50 on 22 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 87 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.5% and over the last three months it rose 23.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 16.9% | ||
| From 52-week high | 0.0% | ||
| Momentum | 76 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 23.6% | ||
| 6-month return | 15.8% | ||
| 12-month return, skipping the last month | 6.0% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 39.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.5% | ||
| Liquidity | 94 · Strong | Trades actively. | |
| Average daily value traded | 23.48M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 26 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.3% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.5% |
|---|---|
| 1 month | +8.1% |
| 3 months | +23.6% |
| 6 months | +15.8% |
| 1 year | +14.5% |
| 3 years | +15.0% |
| 5 years | −50.6% |
Signals
| 50-day / 200-day average | 248.99 / 233.91 |
|---|---|
| Golden / death cross (60 days) | Golden, 38 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 9.75 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Mar 2026 | EUR 0.7400 |
| 28 Mar 2025 | EUR 0.7400 |
| 2 Apr 2024 | EUR 0.7400 |
| 30 Mar 2023 | EUR 1.4400 |
| 28 Mar 2022 | EUR 1.2600 |
| 29 Mar 2021 | EUR 0.7100 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.